annual meeting program - American Society of Clinical Oncology

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION
Genitourinary (Prostate) Cancer
Display Time: 8:00 AM - 12:00 PM
Display Location: E450a
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E Hall D2
CME credit: 1
Track(s): Genitourinary Cancer
Monday, June 7, 2010
Andrea Lynne Harzstark, MD—Co-Chair
University of California, San Francisco
Daniel W. Lin, MD—Co-Chair
University of Washington
Discussion
12:00 PM Johann Sebastian De Bono, MD, PhD (Abstracts #4544–4549)
Drug Development Unit, The Royal Marsden NHS Foundation Trust and
The Institute of Cancer Research
Biomarkers of Response in Prostate Cancer
Discussion
12:15 PM Robert Dreicer, MD (Abstracts #4550–4552)
Cleveland Clinic Taussig Cancer Institute
Can Immunotherapy Be Personalized?
Discussion
12:25 PM Celestia S. Higano, MD (Abstracts #4553–4557)
University of Washington
Novel Therapies and Response Predictors for CRPC
Discussion
12:40 PM Matthew Raymond Smith, MD, PhD (Abstracts #4558–4560)
Massachusetts General Hospital
The Impact of ADT on Bone and Brain
Discussion
12:50 PM Joel B. Nelson, MD (Abstracts #4561–4565)
University of Pittsburgh
Risk Identification, Chemoprevention, Surveillance, and Neoadjuvant Therapy in
Early Prostate Cancer
Brd. 1 A gene expression signature associated with sensitivity to the multikinase
inhibitor dasatinib: Implications for development of a noninvasive biomarker
for personalized therapy based on circulating tumor cell analysis. (Abstract
#4544)
N. Mitsiades, Y. Antipin, B. Reva, N. Schultz, D. C. Danila, C. C. Sung, A. Anand,
C. Sander, H. I. Scher
Brd. 2 Bone scan “flare” in patients receiving abiraterone acetate (AA) for
metastatic castration resistant prostate cancer (mCRPC): Analysis of data
from a phase II study of the Department of Defense Prostate Cancer Clinical
Trials Consortium. (Abstract #4545)
S. K. Shah, C. J. Ryan, C. Kilian, A. Hubbell, T. S. Kheoh, C. M. Haqq, A. Molina,
E. J. Small
Brd. 3 Circulating tumor cells (CTC) and prostate specific antigen (PSA) as
response indicator biomarkers in chemotherapy-naïve patients with
progressive castration-resistant prostate cancer (CRPC) treated with
MDV3100. (Abstract #4546)
A. Anand, H. I. Scher, T. M. Beer, C. S. Higano, D. C. Danila, M. Taplin,
E. Efstathiou, M. Hirmand, C. L. Sawyers, G. Heller, Prostate Cancer Clinical
Trials Consortium
335
MONDAY